The market for polymeric biomaterials is growing quickly, but despite this growth, it is widely recognised in the industry that the ‘holy grail’ solution has not yet been developed. The ideal biomaterial for use in regenerative medicine must: be biocompatible; promote tissue regeneration; have non-toxic biodegradation, have mechanical properties suited to the host tissue and good handling properties in a clinical environment.
Our people have developed a patented range of novel polymeric 3-D printing resin-inks that promise, uniquely, to meet all of the above requirements and offer important advantages over the next best alternatives. The polymers and their degradation products are non-toxic and their properties can be tuned to suit a wide range of tissue regeneration applications. These 3-D printable resin-inks will enable medical implants to be fitted to the exact shape and dimensional requirements of each patient, optimising outcomes in applications such as cancer treatment, degenerative spinal conditions and reconstructive surgery. Initial in-vitro and in-vivo testing has provided strong evidence of the anticipated biocompatibility and tissue regeneration properties that will enable multiple stakeholders in the health sector to benefit from improved treatment options for a range of life-changing conditions, not least the patients themselves.
Our people have developed a patented range of novel polymeric 3-D printing resin-inks that promise, uniquely, to meet all of the above requirements and offer important advantages over the next best alternatives. The polymers and their degradation products are non-toxic and their properties can be tuned to suit a wide range of tissue regeneration applications. These 3-D printable resin-inks will enable medical implants to be fitted to the exact shape and dimensional requirements of each patient, optimising outcomes in applications such as cancer treatment, degenerative spinal conditions and reconstructive surgery. Initial in-vitro and in-vivo testing has provided strong evidence of the anticipated biocompatibility and tissue regeneration properties that will enable multiple stakeholders in the health sector to benefit from improved treatment options for a range of life-changing conditions, not least the patients themselves.
Location: United Kingdom, England, Nottingham
Employees: 1-10
Total raised: $2.22M
Founded date: 2018
Investors 2
| Date | Name | Website |
| - | BioCity | biocity.co... |
| - | Startup Fu... | sfccapital... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 28.07.2021 | - | $2.22M | DSW Ventur... |
Mentions in press and media 10
| Date | Title | Description |
| 28.07.2022 | BMF to accelerate microprinting expansion after raising another $43M | Microscale 3D printer manufacturer Boston Micro Fabrication (BMF) has announced the closure of a $43 million Series C funding round. Led by Chinese VC firm Shenzhen Capital Group Co. (SCGC), the investment comes at a time of significant gro... |
| 15.10.2021 | DSW Ventures promotes Eleanor Boardman to support growth | DSW Ventures, the venture capital investment business of the Dow Schofield Watts group, has promoted Eleanor Boardman to Investment Manager in a period of significant growth for the regional VC. |
| 07.10.2021 | The global biomaterials market was valued at $122.92 billion in 2020 and is expected to reach $725.88 billion by 2031, growing at a CAGR of 17.98% between 2021 and 2031 | New York, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Biomaterials Market - A Global and Regional Analysis: Focus on Applications, Product Types, and Countries - Analysis and Forecast, 2021-2... |
| 29.07.2021 | 3D printing transforming medical implants: Nottingham’s medtech picks up £1.6M funding | A medtech company based in Nottingham, 4D Biomaterials, which has developed a new biomaterial used for 3D printing medical implants, has picked up £1.6 million in a recent funding round. Investors galore The investment round was led by DSW ... |
| 29.07.2021 | Medtech firm raises £1.6m for 3D printed implants | A medtech company which has developed a new biomaterial used for 3D printing medical implants has completed a £1.6m funding round. |
| 29.07.2021 | Mercia Asset Management : Medtech firm raises £1.6m for 3D printed implants | A medtech company which has developed a new biomaterial used for 3D printing medical implants has completed a £1.6m funding round. The investment into Nottingham-based 4D Biomaterials was led by DSW Ventures and backed by the MEIF Proof of ... |
| 28.07.2021 | 3D printing transforming medical implants: Nottingham’s medtech picks up £1.6M funding | A medtech company based in Nottingham, 4D Biomaterials, which has developed a new biomaterial used for 3D printing medical implants, has picked up £1.6 million in a recent funding round. Investors galore The investment round was led by DSW ... |
| 28.07.2021 | 4D Biomaterials completes GBP1.6m funding round led by DSW Ventures | A company which has developed a new type of biomaterial that can be used for 3D printing of medical implants has completed a £1.6m funding round. |
| 24.01.2014 | U.K. stent biomaterials project lands $8M grant | The ReBioStent project, led by U.K.-based Ceram, landed a $8 million (€5.8 million) grant to put towards developing new biomaterials and new arterial stents. The ReBioStent project is seeking to develop biodegradable and biocompatible medic... |
| - | 4D Biomaterials | “Our companyis pioneering the commercialisation of a new class of 3D printable resorbable biomaterials for diverse medical applications. Our technologyis based on revolutionary patent-protected polycarbonate-urethane chemistry marketed unde... |